THOMSON REUTERS
CORTELLIS™

# Revance Therapeutics Inc

## COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 12-Apr-2013

**THOMSON REUTERS**
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

# ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

# GLOSSARY

**Number of Drugs in Active Development**

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Number of Inactive Drugs**

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

**Number of Patents as Owner**

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

**Number of Patents as Third Party**

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

**Patents summary table**

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

**Number of Deals**

A count of deals where the company or one of its subsidiaries is the primary company.

**Key Indications**

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

**Key Target-based Actions**

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

**Key Technologies**

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

## TABLE OF CONTENTS



Return to Table of Contents

© 2013 Thomson Reuters All rights reserved



# Revance Therapeutics Inc

## COMPANY OVERVIEW

| | |
|---|---|
| **Company Name** | Revance Therapeutics Inc |
| **Parent Company Name** | Revance Therapeutics Inc |
| **Website** | http://www.revance.com/ |
| **Country** | US |
| **Number of Drugs in Active Development** | 2 |
| **Number of Inactive Drugs** | 0 |
| **Number of Patents as Owner** | 8 |
| **Number of Patents as Third Party** | 0 |
| **Number of Deals** | 1 |
| **Key Indications** | Acne,Rhinitis,Hyperhidrosis,Migraine,Cerebral palsy,Muscle spasm,Strabismus,Temporomandibular joint syndrome,Cervical dystonia,Conjunctivitis,Dental caries,Gram negative bacterium infection,Gram positive bacterium infection,Headache,Herpesvirus infection,Hot flashes,Hyperpigmentation,Joint disease,Myalgia,Neuropathic pain,Onychomycosis,Overactive bladder,Pain,Periodontal disease,Pruritus,Rosacea,Sinusitis,Sweat gland disease,Tinea |
| **Key Target-based Actions** | Botulinum toxin A stimulator,Acetylcholine receptor antagonist,Botulinum toxin B stimulator,Botulinum toxin C1 stimulator,Botulinum toxin D stimulator,Botulinum toxin E stimulator,Botulinum toxin F stimulator,Botulinum toxin G stimulator,Botulinum toxin stimulator,TAT protein stimulator |
| **Key Technologies** | Toxin,Peptide,Biological therapeutic,Dermatological formulation,Dermatological gel formulation,Parenteral formulation unspecified,Freeze drying,Absorption enhancer transdermal,Drying,Formulation preservation,Injectable formulation,Nasal formulation local,Natural product,Oligosaccharide,Ophthalmic liquid formulation,Oral formulation,Patch formulation,Pharmaceutical carrier,Transdermal formulation |

## COMPANY PROFILE

### SUMMARY

Revance Therapeutics, headquartered in Mountain View, CA, is a privately-held biopharmaceutical company. Revance specializes in developing dermatology products using its transdermal delivery technology and tissue remodeling agents.

### LICENSING AGREEMENTS

In December 2007, Medicis was to make an equity investment in Revance , as well as enter into an option agreement to acquire Revance or exclusively license North American rights to Revance's botulinum toxin type A aesthetic product. Medicis would make a $20 million investment in Revance, receiving preferred stock equivalent of almost 10%. Revance would be responsible for manufacturing worldwide, while Medicis had the right to exercise the option upon completion of certain regulatory milestones through the end of phase II development. On exercising the license option, Revance would receive an option payment, milestones and royalties. The companies also agreed to negotiate a development program for the application of Revance's drug delivery technology. In July 2009, Medicis obtained worldwide aesthetic and dermatological rights to the botulinum toxin type A product.

### FINANCIAL

In April 2013, the company raised $33 million from a series E growth financing and at that time, $71 million in convertible debt was converted into the series E preferred stock.

In June 2011, Revance closed $45 million financing.

In November 2008, the company secured $8 million in venture debt financing.

In May 2008, Revance raised a further $8 million from a series C financing, bringing the total raised to $51.2 million.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

## PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|---|---|---|---|
| Inflammatory disease | 1 | 1 | 2 |
| Neurological disease | 1 | 0 | 1 |
| Musculoskeletal disease | 0 | 1 | 1 |
| Infectious disease | 1 | 0 | 1 |
| Dermatological disease | 1 | 0 | 1 |
| Otorhinolaryngological disease | 1 | 0 | 1 |
| Respiratory disease | 1 | 0 | 1 |

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

## Drugs by Highest Status

Active Drugs by Highest Status Chart


Drugs by Highest Status Table

| Development Status | Number of Drugs |
|---|---|
| Phase 2 Clinical | 1 |
| Discovery | 1 |

## DEALS

| Deal Type | Principal | | Partner | | Total |
|---|---|---|---|---|---|
| | Active | Inactive | Active | Inactive | |
| Drug - Early Research/Development | 0 | 0 | 0 | 0 | 1 |

## CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---|---|---|
| Degeneration | 1 | 1 |

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved



THOMSON REUTERS

### Trials by Phase

| Phase | Ongoing | All |
|---|---|---|
| Phase 3 | 1 | 1 |
| Phase 2 | 0 | 1 |

**Phase Definitions**

**Phase 3 Clinical**
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

**Phase 2 Clinical**
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

**Phase 1 Clinical**
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS *

| Indication | As Owner | As Third Party | Total |
|---|---|---|---|
| Cardiovascular disease | 1 | 0 | 1 |
| Endocrine disease | 3 | 0 | 3 |
| Gastrointestinal disease | 3 | 0 | 3 |
| Genitourinary disease | 4 | 0 | 4 |
| Immune disorder | 2 | 0 | 2 |
| Musculoskeletal disease | 6 | 0 | 6 |
| Neoplasm | 4 | 0 | 4 |
| Ocular disease | 3 | 0 | 3 |
| Metabolic disorder | 4 | 0 | 4 |
| Mouth disease | 1 | 0 | 1 |
| Neurological disease | 6 | 0 | 6 |
| Nutritional disorder | 1 | 0 | 1 |
| Prophylaxis | 1 | 0 | 1 |
| Respiratory disease | 2 | 0 | 2 |
| Infectious disease | 5 | 0 | 5 |
| Injury | 2 | 0 | 2 |
| Inflammatory disease | 3 | 0 | 3 |

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

| | | | |
|---|---|---|---|
| Otorhinolaryngological disease | 3 | 0 | 3 |
| Dermatological disease | 12 | 0 | 12 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved



THOMSON REUTERS

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE**: Highest status refers to highest development of that drug for one of the active companies

### RT-001, Revance Therapeutics

| | |
|---|---|
| **Drug Name** | RT-001, Revance Therapeutics |
| **Key Synonyms** | |
| **Originator Company** | Revance Therapeutics Inc |
| **Active Companies** | Revance Therapeutics Inc |
| **Inactive Companies** | |
| **Highest Status** | Phase 2 Clinical |
| **Active Indications** | Migraine, Hyperhidrosis, Acne |
| **Target-based Actions** | Botulinum toxin A stimulator |
| **Other Actions** | Analgesic, Dermatological agent |
| **Technologies** | Dermatological formulation, Biological therapeutic, Dermatological gel formulation, Peptide, Toxin |
| **Last Change Date** | 26-Mar-2013 |

### RT-401

| | |
|---|---|
| **Drug Name** | RT-401 |
| **Key Synonyms** | |
| **Originator Company** | Revance Therapeutics Inc |
| **Active Companies** | Revance Therapeutics Inc |
| **Inactive Companies** | |
| **Highest Status** | Discovery |
| **Active Indications** | Rhinitis |
| **Target-based Actions** | Botulinum toxin A stimulator |
| **Other Actions** | |
| **Technologies** | Biological therapeutic, Parenteral formulation unspecified, Peptide, Toxin |
| **Last Change Date** | 12-Oct-2012 |

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved



THOMSON REUTERS

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

Return to Table of Contents